Drug Patents owned by Teva Pharms Intl

1. Drug name - AMRIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7790199 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

US7829121 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

US9375410 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

US9399025 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

US8877245 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

US7544372 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

US7820203 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

US7387793 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Feb, 2025

(2 years from now)

Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient

Treatment: Relief of muscle spasm

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
30MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

2. Drug name - SYNRIBO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6987103 TEVA PHARMS INTL Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents Oct, 2026

(4 years from now)

Drugs and Companies using OMACETAXINE MEPESUCCINATE ingredient

Treatment: Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml)

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
3.5MG/VIAL POWDER;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.